ResearcherCentre National de la Recherche ScientifiqueNo recent work listed
Anthony Gonçalvès
Matched on ORCID iD 0000-0001-7570-7439; OpenAlex author ID A5006642161. Sources: ClinicalTrials.gov.
Their work
- Papers
- 6
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 trial
Papers 6
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
- Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
- A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗
- Current knowledge on pancreatic cancer. Co-author DOI 10.3389/fonc.2012.00006↗
- Genome profiling of pancreatic adenocarcinoma. Co-author DOI 10.1002/gcc.20870↗
Trials 1
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Olivıer Turrini · 6 shared papers, 2011–2017 · strength 0.20
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Current knowledge on pancreatic cancer. DOI 10.3389/fonc.2012.00006↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Juan Iovanna · 5 shared papers, 2011–2017 · strength 0.18
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Current knowledge on pancreatic cancer. DOI 10.3389/fonc.2012.00006↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Marc F. Giovannini · 5 shared papers, 2011–2017 · strength 0.16
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Jean‐Luc Raoul · 4 shared papers, 2012–2017 · strength 0.14
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Marine Gilabert · 4 shared papers, 2012–2017 · strength 0.14
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Céline Loncle · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Véronique Secq · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Odile Gayet · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Mehdi Ouaïssi · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Pauline Duconseil · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Nelson Dusetti · 3 shared papers, 2015–2017 · strength 0.12
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
- Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
- Jean‐Robert Delpéro · 3 shared papers, 2011–2017 · strength 0.09
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus place… DOI 10.1093/annonc/mds135↗
- Paper Genome profiling of pancreatic adenocarcinoma. DOI 10.1002/gcc.20870↗
- Julie Roques · 1 shared paper, 2017 · strength 0.04
- Jonathan Garnier · 1 shared paper, 2017 · strength 0.04
- Fabienne Guillaumond · 1 shared paper, 2017 · strength 0.04
- Rémy Nicolle · 1 shared paper, 2017 · strength 0.04
- Benjamin Bian · 1 shared paper, 2017 · strength 0.04
- Sophie Vasseur · 1 shared paper, 2017 · strength 0.04
- Jean‐Marie Boher · 1 shared paper, 2017 · strength 0.04
- Raul A. Urrutia · 1 shared paper, 2017 · strength 0.04
- Gwen Alyce Lomberk · 1 shared paper, 2017 · strength 0.04
- Jean–Charles Dagorn · 1 shared paper, 2012 · strength 0.04
- Laëtitia Dahan · 1 shared paper, 2012 · strength 0.02
- Laurence Moureau-Zabotto · 1 shared paper, 2012 · strength 0.02
- Éric François · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.